The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. by Pinton, Laura et al.
UCSF
UC San Francisco Previously Published Works
Title
The immune suppressive microenvironment of human gliomas depends on the 
accumulation of bone marrow-derived macrophages in the center of the lesion.
Permalink
https://escholarship.org/uc/item/83g2q664
Journal
Journal for immunotherapy of cancer, 7(1)
ISSN
2051-1426
Authors
Pinton, Laura
Masetto, Elena
Vettore, Marina
et al.
Publication Date
2019-02-27
DOI
10.1186/s40425-019-0536-x
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Pinton et al. Journal for ImmunoTherapy of Cancer            (2019) 7:58 
https://doi.org/10.1186/s40425-019-0536-xRESEARCH ARTICLE Open AccessThe immune suppressive
microenvironment of human gliomas
depends on the accumulation of bone
marrow-derived macrophages in the center
of the lesion
Laura Pinton1, Elena Masetto1, Marina Vettore2, Samantha Solito2, Sara Magri2, Marta D’Andolfi2, Paola Del Bianco1,
Giovanna Lollo3,4, Jean-Pierre Benoit5, Hideho Okada6,7, Aaron Diaz6, Alessandro Della Puppa8
and Susanna Mandruzzato1,2*Abstract
Background: Systemic and local immune suppression plays a significant role in glioma progression. Glioma
microenvironment contains both brain-resident microglial cells (MG) and bone marrow-derived macrophages
(BMDM), but the study of their functional and immune regulatory activity has been hampered until now by
the lack of markers allowing a proper identification and isolation to collect pure populations.
Methods: Myeloid and lymphoid infiltrate were characterized in grade II, III and IV gliomas by multicolor flow
cytometry, along with the composition of the cell subsets of circulating myeloid cells. Macrophages were sorted and
tested for their immunosuppressive ability. Moreover, following preoperative administration of 5-aminolevulinic acid to
patients, distinct areas of tumor lesion were surgically removed and analyzed, based on protoporphyrin IX fluorescence
emission.
Results: The immune microenvironment of grade II to grade IV gliomas contains a large proportion of myeloid cells
and a small proportion of lymphocytes expressing markers of dysfunctional activity. BMDM and resident MG cells were
characterized through a combination of markers, thus permitting their geographical identification in the lesions, their
sorting and subsequent analysis of the functional characteristics. The infiltration by BMDM reached the highest
percentages in grade IV gliomas, and it increased from the periphery to the center of the lesion, where it exerted a
strong immunosuppression that was, instead, absent in the marginal area. By contrast, MG showed little or no
suppression. Functional differences, such as iron metabolism and phagocytosis, characterized resident versus blood-
derived macrophages. Significant alterations in circulating monocytes were present in grade IV patients, correlating
with accumulation of tumor macrophages.
Conclusions: Grade IV gliomas have an alteration in both circulating and tumor-associated myeloid cells and,
differently from grade II and III gliomas, show a significant presence of blood-derived, immune suppressive
macrophages. BMDM and MG have different functional properties.
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Table 1 Participant characteristics
Glioma gradea Meningiomab Controls
II III IV
Sex (n)
Male 7 8 54 3 24
Female 6 4 22 10 11
Median age 42 50 59 57 59
Range 24–70 29–73 27–79 43–74 36–84
IDH status(n)
WT 1 3 72 NA NA
Mutated 12 9 4 NA NA
MGMT (n)
Non-methylated 0 4 35 NA NA
Methylated 6 4 38 NA NA
NA 7 4 3 NA NA
Steroid no yes yes yes no
aFor grade II, n = 13 patients and 13 tissue samples. For Grade III, n = 12
patients and 12 tissue samples. For Grade IV, n = 76 samples and 113
tissue samples
bGrade I and II
n = number
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The concept of the immune privilege of the CNS has re-
cently been revised and it appears now that local im-
munity can adapt to a peculiar environment, directed by
a flexible blood brain barrier and by the presence of un-
conventional lymphatic vessels [1, 2]. Indeed, local im-
munity in the CNS is completely subverted by a growing
tumor, as documented by the presence of a leukocyte in-
filtrate in different brain tumors [3]. Another peculiarity
of the CNS is the presence of microglia (MG) cells, resi-
dent macrophages fulfilling the role of immune surveil-
lance and removal of debris, with a distinct ontogenesis
compared to bone-marrow derived macrophages
(BMDM) that heavily infiltrate tumors [4, 5].
Primary brain tumors are heterogeneous not only in
their genetic and metabolic composition, but also in
their microenvironment. In glioblastoma (GBM), the
presence and role of leukocyte infiltrating cells has been
addressed in both mouse models and in human tumors.
Elegant genetic mouse models have demonstrated that
BMDM and MG are both present in gliomas and possess
distinct transcriptional and chromatin states [6], and
that during GBM growth there is an influx of myeloid
cells in the tumor microenvironment [3, 7], which repre-
sents the main source of tumor-infiltrating macrophages.
However, it is unclear to what extent a mouse model
can recapitulate the human counterpart, given the het-
erogeneity of GBM. Also in grade II and III glioma pa-
tients, an infiltrate of myeloid origin mainly constituted
of macrophages was documented [8, 9] and associated
to shorter overall survival (OS) [10] or correlated to the
pathological grade [11]. However, in all the studies per-
formed in grade II to IV glioma patients, the precise
identification of human MG cells from BMDM lacked
or was limited to morphological evaluation coupled with
immunohistochemical analysis [12], or to subtle differ-
ences in staining intensity of myeloid markers by flow
cytometry, due to the lack of differentially expressed
markers on the two cell types [7]. Recently, the addition
of CD49D marker has been proposed to discriminate
MG from BMDM [6, 10].
Given these constraints, the presence and relevance to
tumor progression of BMDM and of resident MG is un-
clear in human gliomas. We sought to analyze the im-
mune infiltrate in II, III and grade IV gliomas from
freshly resected tissues, and to isolate and characterize
MG from BMDM. Taking advantage of 5-aminolevulinic
acid (5-ALA) administration to grade IV glioma (glio-
blastoma, GBM) patients prior to surgery, which leads
to intracellular accumulation of fluorescent porphyrins
[13], we analyzed separate areas of tumor lesions, from
which we sorted both macrophage populations, thus en-
lightening their different immunological and functional
characteristics.Methods
Patient characteristics
Patients were recruited at the Department of Neurosur-
gery, Padova University Hospital, Italy and their charac-
teristics are shown in Table 1. The ethical committee of
the IOV-IRCCS and of Padova University Hospital ap-
proved all experiments and all patients gave their in-
formed consent. The studies were conducted in
accordance with the Declaration of Helsinki.Blood and tumor samples
Peripheral blood was drawn from patients either at sur-
gery before anesthesia induction, or the day before sur-
gery, and immediately processed. For functional assays
peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient centrifugation on Ficoll-Paque
PLUS (GE Healthcare-Amersham, NJ, USA), as previ-
ously described [14].
All tumors were processed immediately after resection
by enzymatic digestion, using human Tumor Dissoci-
ation Kit (Miltenyi Biotec) and following manufacturer’s
instructions for soft tumors. Before digestion, tissues
were extensively washed with 0.9% sodium chloride so-
lution to remove peripheral blood.Multiparametric flow cytometry
Peripheral blood was stained with monoclonal antibodies
to analyze the presence of different myeloid cell popula-
tions. Staining procedure and immunophenotyping
standardization were the same reported in [15] and are
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bodies for cell subset analysis.
Cell suspension from glioma tissues after enzymatic di-
gestion was labelled with different antibody mixtures to
characterize myeloid and lymphocyte subsets as reported
in Additional file 1: Table S1.
Isolation of myeloid cell subsets and immunosuppressive
assay
Live CD45+/CD33high/CD49D+/HLA-DR+ or live
CD45+/CD33high/CD49D−/HLA-DR+ cell subsets were
separated by FACS sorting (BD FACS ARIA III). The
purity of each fraction was > 90%. Immunosuppressive
activity of myeloid cells isolated either from the periph-
eral blood or from tumor, was performed as detailed in
Additional file 1 and previously described [16].
Cytospin preparation and may-Grünwald-Giemsa (MGG)
staining
Sorted cells were centrifuged (Shandon Cytospin 3 cen-
trifuge) on microscope slides, and cytospins were stained
and analyzed as reported in [16].
RNA-sequencing
CD11b+ cells were obtained by immunomagnetic cell
sorting using anti-CD11b microbeads (Miltenyi Biotec),
following manufacturer’s instruction, or by immunopan-
ning. Single-cell RNA sequencing and data processing
were performed as previously described [10].
Statistics
The Mann-Whitney and the Student t-test were used as ap-
propriate to evaluate statistically significant variations be-
tween groups of samples. To control the False-
Discovery-Rate during multiple comparisons, p-values were
adjusted using the Benjamini-Hochberg procedure. All tests
were two-sided and a P < 0.05 was considered statistically
significant. Absence of significance was not reported for
brevity. Spearmann correlation and linear regression model
were used to test the association between parameters.
Statistical analyses were performed using the Sigmaplot
software (Systat Software Inc., CA, USA) and RStudio
(RStudio: Integrated Development for R. RStudio, Inc.,
Boston, MA).
Results
Leukocyte infiltrate with immunosuppressive features
increases from grade II to grade IV gliomas
To evaluate the immune web at the tumor site, we per-
formed a detailed analysis of the leukocyte infiltrate by
multicolor flow cytometry (Additional file 1: Table S1) in
tumor tissues from untreated grade II, III and IV glioma
patients (Table 1), processed immediately after resection.
We found a recurrent presence of CD45+ leukocytesinfiltrating human gliomas, increasing significantly in
grade IV gliomas (median 19.6% grade II vs 28.6% grade
III vs 40.3% grade IV). Of note, the majority of infiltrat-
ing leukocytes consisted of CD33+ myeloid cells (91.2,
92.2 and 85.6% in grade II, III and IV gliomas respect-
ively), mainly composed by CD33+/HLA-DR+ macro-
phages (mean of 85.2% in grade II, 84.3% in grade III
and 64.7% in GBM), and by a lower percentage of
CD33dim/HLA-DR− polymorphonuclear cells (PMNs,
10.8% in grade II, 10.2% in grade III and 15.8% in GBM)
(Fig. 1a). T cells were also present, although in a small
amount, but both CD4+ (defined as CD3+/CD8−) and
CD8+ T cells increased significantly from grade II to
grade IV gliomas (Fig. 1b), paralleled by a significant ex-
pression of PD-1, increasing from grade II to grade IV
(mean of 45.4% vs 73.9% vs 79.0% in grade II, III and IV
for CD3+CD8− cells, and 64.8% vs 74.9% vs 80.4% in
grade II, III and IV for CD3+CD8+ cells, respectively), as
shown in Fig. 1c. Another molecule associated to T cell
dysfunction, LAG-3, was present on all T cells infiltrat-
ing grade II to IV gliomas, although at lower levels than
PD-1, and its expression peaked in grade III gliomas
(Fig. 1d).
As far as PD-L1 expression in the glioma microenvir-
onment is concerned, the highest expression was present
on CD45− cells, with a progressive and significant in-
crease from grade II to grade IV gliomas, as already re-
ported at transcriptional level by Wang et al. [17].
However, PD-L1 expression was also present on macro-
phages, in line with previous results [18, 19], with a sig-
nificant increase in grade IV tumors (Fig. 1e). PMNs
show a lower PD-L1 expression as compared to macro-
phages and CD45− cells and no statistically significant
differences were observed. Interestingly, when we con-
sidered CD8+ T cells expressing PD-1 higher than 60%
(39 out of 45 GBM cases), we observed a significant cor-
relation with PD-L1-expressing macrophages (Fig. 1f ),
but not with PMN and with CD45− cells.
Identification of a set of markers distinguishing MG from
BMDMs
Given the abundance of macrophages in GBM infiltrate,
we set out to identify brain resident MG from circulating
monocytes that migrate to the tumor site. Until now, an
unequivocal phenotypic and functional distinction be-
tween these two cell types is missing, and one marker
differentially expressed between MG and BMDM is
CD49D [6, 20]. We thus began to discriminate macro-
phages with this marker, in conjunction with CD45,
CD33 and HLA-DR. This analysis revealed the presence
of two main myeloid cell subsets identified as CD45+/
CD33+/HLA-DR+/CD49D+, corresponding to BMDM,
and CD45+/CD33+/HLA-DR+/CD49D−, corresponding
to MG cells (Fig. 1g). After cell sorting, morphological
a b c
d e f
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Fig. 1 (See legend on next page.)
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Fig. 1 Distribution of tumor-infiltrating leukocytes in gliomas. a and b Box Plots show the median, 25th and 75th percentile of the frequency of
tumor-infiltrating leukocytes, whiskers extend to 1.5 inter-quartile range and outliers are shown by dots. Grade II gliomas are yellow, grade III
gliomas orange and GBM red (n = 13 for CD45+, CD33+, CD33+/HLA-DR+, CD33dim/HLA-DR− cells in grade II gliomas, n = 12 for grade III gliomas
and n = 51 in GBM; n = 10 for CD3+, CD4+, CD8+ cells in grade II gliomas, n = 6 for grade III gliomas and n = 46 for GBM patients). CD45+ cells
were gated among live cells, CD33+ cells among CD45+ leukocytes, myeloid subsets CD33+/HLA-DR+ and CD33dim/HLA-DR− were gated on
CD33+ cells, while lymphocytes on CD33−/SSClow cells. c PD-1 and (d) LAG-3 expression in CD3+CD8− and CD3+CD8+ cells in gliomas (n = 9 for
grade II gliomas, n = 5 for grade III gliomas and n = 47 for GBM). e PD-L1 expression in CD33+/HLA-DR+ (n = 10 for grade II gliomas, n = 7 for
grade III gliomas and n = 50 for GBM), CD33dim/HLA-DR− (n = 9 for grade II gliomas, n = 7 for grade III gliomas and n = 50 for GBM), and CD45−
cells (n = 10 for grade II gliomas, n = 7 for grade III gliomas and n = 46 for GBM). f Linear regression model between PD-L1 expression in CD33+/
HLA-DR+ cells and PD-1 expression in CD8+ T cells (p = 0,00683). g Macrophage subset identification based on CD33high, PMN (CD33int/SSChigh
cells) exclusion and CD49D and HLA-DR markers in GBM (left plot). The two populations were purified by FACS sorting and MGG stained (right
images). h Intensity of morphological parameters (left histogram), CD45, CD33, HLA-DR (middle histogram), and PpIX expression (right histogram;
n = 23, for CD45 analysis n = 14) in BMDM (green) and MG (blue). Mann-Whitney test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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two populations have distinct morphological characteris-
tics; compared to resident MG CD49D− cells, CD49D+
BMDM are larger cells (22.7 μm as mean diameter of
BMDM vs 11.5 μm of MG), with an abundant and vacuo-
lated cytoplasm, and smaller nucleus-to-cytoplasm ratio, a
typical morphology of tissue macrophages (Fig. 1g). These
morphological differences were also confirmed by flow cy-
tometry, as BMDMs show a significantly higher
forward-scatter (FSC) than MG (Fig. 1h). Moreover, the
two macrophage populations had a characteristic pheno-
type, since BMDMs express HLA-DR, CD45, CD33
markers at higher levels than MG cells (Fig. 1h middle
panel), thus permitting their unambiguous identification.
BMDM infiltration in GBM is responsible for the
immunosuppressive gradient stemming from the tumor
core
GBM growth follows a multilayer pattern of lesion spread
driven by hypoxia and characterized by a central necrotic
area [21] and a marginal area [22–25]. We analyzed differ-
ent layers of the tumor mass to understand if myeloid cell
infiltrate differs between the center and the marginal
areas. Tissue sampling was performed by 5-ALA assisted
surgery combined with MRI-neuronavigation. Following
preoperative administration of 5-ALA, fluorescent proto-
porphyrin IX (PpIX) is synthesized and can be visualized
under violet light with different fluorescence intensities,
allowing the identification of the central necrotic area
(core), corresponding to the inner non fluorescent tissue,
an intermediate area, brightly fluorescent (intense), and a
marginal area corresponding to a dimly fluorescent tissue
(margin), (Fig. 2a). A representative example of this ana-
lysis is shown in Fig. 2b, demonstrating the coexistence of
BMDM and MG in the lesion, but with different propor-
tions in the center or in the marginal area. Collectively, in
30 patients in which the three matched tissues were indi-
vidually analyzed, BMDM represented 15.5% +/− 3.9%
(mean ± SE) of total macrophages in the margin, but their
concentration rose in the center of the lesion, both in thecore (64.2 +/− 5.1%) and in the intense fluorescent area
(59.5 +/− 5.3%) (Fig. 2c). On the contrary, the presence of
MG cells in the GBM microenvironment followed inverse
proportions in the center versus the marginal area (27.3%
+/− 4.9% in the core, 35.9% +/− 5.5% in the intense fluor-
escent area and 77.9% +/− 3.9% in the margin, Fig. 2c).
We then evaluated the presence of macrophages in grade
II and III glioma tissues, in which surgery was performed
without 5-ALA. In grade III tumors, resected samples cor-
responded to enhancing regions at T1-Weighted Images
with gadolinium, while grade II gliomas were without con-
trast enhancement. We observed that the presence of
BMDM in grade II and III gliomas was low or absent
(mean of 13.7% in grade II and 12.6% in grade III gliomas;
Fig. 2c, right histograms), with an infiltration profile simi-
lar to that of the marginal area of GBM tissue. IDH status
had no impact on the MG/BMDM infiltrate: in 76 GBM
analyzed, 4 samples were mutated, but with no significant
difference in terms of macrophage composition; the same
applies to grade II, in which only one sample out of 13 an-
alyzed was wild type, and to grade III, which harbored 3
wild type samples out of the 12 collected, but no major
differences were observed in terms of immune cell
composition.
Taken together, these results suggest that BMDM ac-
cumulation characterizes grade IV gliomas, and that
these cells progressively infiltrate in the lesion from the
marginal to the central area. We tested the hypothesis
that macrophages possess an immune suppressive activ-
ity conditioned not only by the ontogeny, but also by the
context of the tumor microenvironment. To this end, we
sorted BMDM and MG cells both in the center and in
the marginal tumor area, and tested their ability to inter-
fere with the proliferation of activated T cells. Results
from these experiments revealed that when BMDMs are
located in the core of the lesion, they possess an im-
munosuppressive activity (range, 21.3–78.4%), which is
higher than that exerted by MG cells sorted from the
same central part of the lesion (range,4.9–46.5%). In the
marginal part of the tumor, instead, both populations
ab
c d
Fig. 2 (See legend on next page.)
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Fig. 2 MG and BMDM characterization in different glioma areas and analysis of their immune suppressive activity. a Surgical microscopic view
under blue light (left panel) and preoperative Magnetic Resonance T1-weighted image after gadolinium administration (right panel) of a patient
with a left deep GBM. Different fluorescence intensities are detected in distinct tumor areas: a bright fluorescence corresponds to the ring tumor
enhancement at MRI, a dim fluorescence is present in the peritumoral infiltration, lack of fluorescence is in the central necrotic area. b
Representative flow cytometry panels and (c), cumulative data of BMDM (green) and MG (blue) cells in three tumor layers identified by 5-ALA
fluorescence in GBM tissues (n = 24 core, n = 30 intense fluorescence, n = 19 marginal samples) (left histograms) and from grade II (n = 11) and III
(n = 9) glioma patients (right plots). d Immunosuppressive activity of BMDM (green) and of MG (blue) isolated by FACS sorting from the central
intense fluorescence layer, or from the surrounding peritumoral space of GBM patients (n = 7 for BMDM in the center, n = 4 for MG in the center;
n = 3 for BMDM in the margin, 4 for MG in the margin). MG tested from grade II (n = 2) and grade III (n = 3) gliomas. Comparison by Mann-
Whitney test, ***p < 0.001
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grams), thus highlighting that BMDMs acquire immune
suppressive ability as they migrate to the center of the
lesion. We also evaluated the functional activity of
sorted MG cells in grade II and III gliomas, the main
macrophage population in these tumor tissues, and ob-
served that these cells have a negligible immunosuppres-
sive function in both grade II and in grade III gliomas
ranging from 0 to 11% (Fig. 2d, right histogram).
These results highlight that the immunosuppression
present in GBM tumor microenvironment depends on
the infiltration of BMDM in the central part of tumor
mass and that BMDMs and MG have an intrinsic differ-
ent tolerogenic capability.
PpIX fluorescence emission: a new tool to identify
immunosuppressive macrophages in GBM tissues
Taking advantage of 5-ALA administration to GBM pa-
tients, we analyzed fluorescence emission of PpIX in tumor
tissue by tumor cells, evaluated as CD45− in the center of
the lesion, but also from all the leukocyte subsets. Contrary
to expectations that 5-ALA is mainly metabolized by tumor
cells, we observed that the strongest emission of fluores-
cence was from the macrophages in all three layers, with
different intensity between MG and BMDM in each layer
(Fig. 3 a and b); the fluorescence of PpIX from BMDMs
was always brighter than that of MG cells. PpIX emission
can thus be used as a cell marker capable of discriminating
between the two populations (Fig. 1h, right panel) along
with morphological markers (FSC and SSC, Fig. 1h, left
panel) and with CD45, CD33, HLA-DR (Fig. 1g, middle
histograms). To evaluate if the combination of the previ-
ously described markers could lead to the unambiguous
discrimination of BMDM and MG, we performed an un-
supervised T-Distributed Stochastic Neighbor Embedding
(t-SNE) analysis by combining all these parameters, and we
obtained the clusterization of live cells present at the tumor
site (Fig. 3c, first left plot). By gating on the two main clus-
ters (Fig. 3c, blue and green area in the upper part) and
analyzing the expression of the single markers, we could
clearly identify the phenotype of MG and BMDM, thus re-
inforcing our results on the identification of macrophage
subsets with this marker combination (Fig. 3c).The progressive increase in the accumulation of
5-ALA-induced PpIX in BMDM from the marginal to
the central area suggests not only that iron metabolism
is sustained in myeloid-infiltrating cells, but also that it
is higher than that of tumor cells. To evaluate the role of
iron metabolism in the tumor microenvironment of
GBM, we analyzed an external data set of eight cases of
GBM that were profiled following CD11b selection ei-
ther via magnetic beads or immunopanning and sub-
jected to single-cell RNA sequencing [10]. Classification
of macrophage lineage and of tumor cells was performed
using previously described gene signature [10]. Analysis
of the expression of the genes implicated in iron metab-
olism in BMDM, MG and tumor cells showed a signifi-
cant overexpression of many of these genes in BMDM,
compared to MG cells (Fig. 4). In fact, genes involved in
iron uptake (CD163 and TFRC), storage (FTL, HAMP,
ACO1 and NCOA4), metabolism (FECH, UROS, UROD,
HMBS, CPOX and ALAD), and catabolism (BLVRA and
HMOX1) are all overexpressed in BMDM (Fig. 4). Col-
lectively, these results highlight that BMDM possess a
sustained iron-recycling metabolism.BMDM are target of preferential incorporation by lipid
nanocapsules in the tumor microenvironment of grade IV
gliomas
We previously demonstrated that lipid nanocapsules
(LNCs) loaded with a cytotoxic drug efficiently target
immune suppressive monocytic cells in the blood of
melanoma patients [26]. We thus evaluated the in-
corporation of fluorochrome-labeled DiD LNCs by
the cell suspensions obtained after dissociation of the
central area of the GBM tissue with intense PpIX
fluorescence, in which immune suppressive myeloid
cells are abundant. Results indicate that lymphocytes,
PMN and CD45− cells have a low internalization cap-
ability, while DiD fluorescence is increased in macro-
phage populations, in particular in BMDMs, that
show significantly higher levels of uptake as compared
to MG. The immunosuppressive BMDM population is
therefore the preferential target of this nanocarrier
system. (Fig. 5 a, b).
ab
c
Fig. 3 (See legend on next page.)
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Fig. 3 Fluorescence emission of PpIX from cell subsets in the tumor microenvironment. a Representative flow cytometry plot and (b) cumulative
analysis of 5-ALA fluorescence emission by CD45− cells (pink), MG (blue) and BMDM (green) (n = 15 core samples, n = 21 intense fluorescence
samples and n = 13 margin samples). c t-SNE analysis of live cells infiltrating the intense fluorescence layer (n = 11 samples) of GBM patients.
Combined analysis on the following parameters: CD45, CD33, HLA-DR, CD49D, PPIX. In the two main clusters obtained after t-SNE analysis (blue
and green populations), the expression of the single markers was analyzed (blue and green histograms). Comparison by Mann-Whitney
test, **p < 0.01
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circulating monocytes
Since immunosuppressive macrophages that infiltrate
GBM are blood-derived, we investigated the characteris-
tics of circulating monocytic cells in the same patients
and, as previously reported [7, 27], observed a higher
percentage of circulating monocytes compared to a
group of age and gender matched healthy donors (HD)
(Fig. 6a). As an additional comparison, we also took into
account a group of patients with WHO grade I and II
meningioma (Table 1) and observed a significantly
higher percentage of monocytes in GBM patients only
(Fig. 6a). Given that preoperative steroids are adminis-
tered to both meningioma and GBM patients, this result
indicates that monocyte alterations strictly depend on
tumor type, and rule out the contribution of steroid
treatment.Fig. 4 Gene expression analysis of genes involved in heme metabolism in
iron metabolism genes obtained from scRNAseq of neoplastic and immun
single-cells suspensions were subjected to scRNA-seq. Bars denote mean e
Significance assessed via a t-test, *p < 0.05, **p < 0.01, ***p < 0.001We next evaluated in detail the composition of blood
monocytes to discriminate the three main subsets that
are classical monocytes (C=CD14+/CD16−), intermedi-
ate (I=CD14+/CD16+) and non-classical subsets
(NC=CD14−/CD16+) (Fig. 6b), and further analyzed the
expression of CCR2 on their surface (Fig. 6d), as it is
known that CCL2 chemokine promotes monocyte accumu-
lation at the tumor site, and has already been implicated in
the recruitment of myeloid cells in glioma [28, 29]. Results
indicate a decrease of intermediate monocytes (Fig. 6c) but
a significant increase of CCR2+ cells among the same sub-
set (Fig. 6e), thus suggesting that this population is actively
recruited at tumor site. We then tested the presence of a
significant association between the levels of circulating and
tumor-infiltrating myeloid cells and observed a positive cor-
relation between the percentage of circulating classical
monocytes and that of macrophages at tumor site (Fig. 6f),BMDM (green), MG (blue) and tumor cells (pink). Expression of heme-
e cells from primary gliomas. Both whole tumor and CD11b-purified
xpression and whiskers denote the standard error of the mean.
ab
Fig. 5 Uptake of LNCs loaded with DiD by cell subsets in GBM. a
Representative example showing DiD fluorescence intensity of
different leukocyte populations and CD45− tumor cells after over-
night incubation with DiD-loaded LNCs of cell suspensions. b
Fluorescence intensities of DiD-loaded LNCs and blank-LNCs in
different GBM subsets. N = 9 for BMDM, MG, CD45− tumor cells and
lymphocytes; n = 6 for PMN. Mean and SE are reported; Mann-
Whitney U test *p < 0.05, **p < 0.01, ***p < 0.001
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are the first to be recruited from the bone marrow and have
the potential to give rise to intermediate monocytes first
and later to non-classical monocytes [30].
Discussion
Recently, the immune microenvironment in gliomas has
been the subject of intense research. A great impulse has
been given by deconvolution studies, which, with the use
of a bioinformatic approach, showed that MG and BMDM
possess a different transcriptional program [10, 31]. Our
work extends previous studies as follows: first, we were
able to isolate and test the immune suppressive ability of
BMDM and MG, going beyond the transcriptional profile
and testing their effective immunoregulatory function;
second, by exploiting an imaging surgical technique, wedocumented the regional contribution to immune sup-
pression of each macrophage cell subset, and third, we
demonstrated that isolated microglia cells from grade II
and III gliomas lack immunosuppressive activity. Collect-
ively, these results indicate that macrophages’ tolerogenic
properties in GBM depend not only by ontogeny, but also
by the regional distribution in the tumor area.
The characterization of BMDM and MG after cell
sorting revealed that blood-derived macrophages were
bigger in size and were more complex than their resi-
dent counterparts (Fig. 1 g and h), a morphological fea-
ture in line with the presence of what appears to be
remnants of ingested cells, revealing different phagocytic
capacities as highlighted by LNC incorporation. Based
on previous microscopic and morphological studies,
both BMDM and MG were considered activated cells in
a growing brain tumor [32–34]. However, our results
demonstrate that such cells differ, at least as far as their
immunosuppressive activity and phagocytic activity is
concerned. In fact, resident macrophages participate
only marginally in the phenomenon of immune suppres-
sion, and this aspect suggests that blood monocytes re-
cruited to the tumor are already committed to a
program of immune suppression. However, they only ac-
quire full immune suppressive ability in the center of the
lesion, and not in the surrounding region. In this regard
the concept of “heritage” carried by these cells, due to
their different origin and identified by the CD49D
marker, is of translational importance because it shows
that BMDMs are endowed with a high immunosuppres-
sive potential, a trait that renders them particularly
harmful for patient outcomes, but at the same time it
also highlights a potential target of intervention to block
their activity and/or recruitment.
Local immunosuppression in GBM also extends to the
presence of checkpoint inhibitors on T cells and to their
ligands on tumor cells and on innate immune cells, thus
showing that multiple mechanisms contribute to the im-
mune suppressive microenvironment in these patients.
Interestingly, these checkpoints show lower expression
in grade II and III gliomas, in line with previous results
on PD-L1 [17, 35], but our results also expanded the
analysis on the T cell counterpart. The functional associ-
ation in GBM of a small, but recurrent population of T
cells, bearing a high PD-1 expression, and of its ligand
on macrophages (Fig. 1f ), suggests that this axis plays a
significant role in the suppression exerted by tumor
macrophages. Given the low number of IDH mutant pa-
tients among the GBM group and vice versa for grade II
and III gliomas, PD-L1 and PD-1 distribution segregates
with patients IDH status, as previously reported [35].
The presence of a recurrent immunosuppressive infil-
trate in grade IV gliomas should be taken into account
in new clinical studies of immunotherapy, as a large
a b
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Fig. 6 Characterization of monocyte dysregulation in GBM patients. a Boxplots of the distribution of percentage of monocytes in blood samples from HD
(n= 12), GBM (n= 24) and meningioma (MNG) (n= 13) patients, calculated as HLA-DR+ cells among PBMCs. b Analysis of monocyte subsets in whole
blood using CD14 and CD16 markers. Dot plot gated on PBMCs shows classical monocytes (C) CD14high/ CD16− and intermediate subset (I) and a non-
classical subset (NC). (c) Distribution of C, I and NC monocytes in meningioma (MNG, n= 13) and glioblastoma patients (GBM, n= 24) in comparison to
HDs (n= 12). d Representative example of CCR2 expression on monocyte subsets in GBM patients. White histograms show fluorescence minus one (FMO)
controls, black histograms refer to MFI values of CCR2+ cells of healthy donor, while grey histograms indicate MFI values of CCR2+ cells among C (blue), I
(orange), and NC (green) monocytes of GBM patients. e Cumulative data showing CCR2 expression in MNG (n= 13) and GBM patients (n= 24) compared
to HDs (n= 12). Mann-Whitney test for statistical significance between pairwise groups. f Correlation between the percentage of classical monocytes in
PBMCs and that of macrophages among GBM-infiltrating leukocytes. Spearman’s rank-order correlation on 20 paired samples
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prove its efficacy [36]. Moreover, despite the possibility
to induce neoantigen-specific T cells in vaccinated GBM
patients, capable to successfully traffic to the tumor site,
such T cells are insufficient to induce clinically relevant
responses [37, 38]. Thus, blocking the immune suppres-
sion in these patients appears a necessary step to stimu-
late an efficient anti-tumor immune response, and
targeting the myeloid infiltrate in GBM represents a new
therapeutic strategy for future clinical studies, in com-
bination with immune stimulation.
Our data show that the functional differences between
MG and BMDM extend beyond the immune suppression
task, since their iron-related metabolism also shows signifi-
cant differences in these macrophages. Iron metabolism is
an important hallmark for macrophages, and it is not sur-
prising that blood-derived cells maintain such characteris-
tics when recruited to the tumor lesion. Moreover, several
studies suggest that tumor cells exploit this macrophage
ability to supply iron to the tumor [39, 40]. In fact, in re-
sponse to inflammatory conditions, macrophages increase
the iron storage, while in the tumor microenvironment they
release iron, which is required to sustain tumor survival
and growth [40]. Whether the iron metabolism is linked to
the program of immune suppression remains to be ex-
plored, but our data open up the possibility of targeting this
circuit with drugs interfering with this pathway.
The alteration of the myeloid compartment in GBM pa-
tients is also confirmed by the decrease of circulating
CD16+ intermediate monocytes showing an increase of
CCR2 expression. It is currently believed that classical
monocytes are the first cell subset to transit from the bone
marrow to the circulation, and they have the potential to
give rise to intermediate monocytes, and later to
non-classical monocytes [30]. Therefore, the reduction in
intermediate monocytes present in GBM patients, coupled
with the simultaneous increase in CCR2 expression in this
cell subset, suggests the possibility that CD14+/CD16+
monocytes represent the cell subset actively recruited to
the tumor in GBM patients. This hypothesis is in line with
the positive correlation between the percentage of classical
monocytes present in the peripheral blood of GBM pa-
tients and the percentage of macrophages in the tumor
(Fig. 6f), thus suggesting an active process of monocyte re-
cruitment dictated by GBM milieu, in line with murine
fate mapping studies [6]. It thus appears that circulating
myeloid cells also have a critical role in GBM, as they are
the source sustaining the accumulation in the lesion and
therefore blocking macrophage recruitment to the tumor
might represent another strategy to limit tumor growth.
Conclusions
In this study, we demonstrate the presence of an exten-
sive immunosuppressive microenvironment in GBM, butnot in grade II and III gliomas, due to the presence of
blood-derived macrophages, expressing PD-L1, and of T
cells showing markers associated to impaired T cell
function. Our study shows that macrophages of bone
marrow origin migrate to the tumor site and accumulate
in the central area of GBM, exerting a strong immune
suppression, while resident microglia exerts low or no
immunosuppressive function. Microglia constitutes the
majority of macrophages in grade II and III gliomas and
is devoid of significant immunosuppressive activity. Be-
sides the tolerogenic properties, differences exists be-
tween resident versus blood-derived macrophages, such
as iron metabolism and ability to efficiently internalize a
nanocarrier system that could be used to target them at
tumor site.
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